Sunovion Pharmaceuticals Inc.

Pgi Drug Discovery LLC

Sharon Rae Engel

Liming Shao

Michael Charles Hewitt

Jianguo Ma

Fengjiang Wang

Una Campbell

Scott C Malcolm

Larry Wendell Hardy

Patrick Koch

Mark A Varney

Larry R Bush

Kerry Leigh Spear

Scott Christopher Malcolm

John Emmerson Campbell

Rudy Schreiber

Milan Chytil

Seth Ribe

Qun Kevin Fang

Taleen G Hanania

Emer Leahy

Vadim Alexandrov

John E Campell

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Cycloalkylamines as monoamine reuptake inhibitors

Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A, A, R, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders

Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Histamine H3 inverse agonists and antagonists and methods of use thereof

The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.

Tetralone-based monoamine reuptake inhibitors

Growing community of inventors

Hudson, MA, United States of America

Sharon Rae Engel